Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 21Meningioma 6Gastro-enteropancreatic neuroendocrine tumor 6Pheochromocytoma 3Paraganglioma 3Prostatic Neoplasms 2Neuroblastoma 2Medulloblastoma 2Glioma 2Glioblastoma 2Carcinoma, Merkel Cell 2Adenoma, Islet Cell 2Somatostatin Receptor-positive Neuroendocrine Tumor 1Sarcoma, Synovial 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Ependymoma 1Disease Progression 1Digestive System Neuroendocrine Tumor G1 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

zimberelimab 1pembrolizumab 1olaparib 1lutetium Lu 177 dotatate 1lanreotide 1fluorodopa F 18 1cabozantinib 1Sunitinib 1Random Allocation 1Octreotide 1Nivolumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × lutetium Lu 177 dotatate × 1 year × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡